parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in podocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 9632

receipt 9641: NFASC in dopamine neurons, braak

power: full sample -0.30 (p 0.221, n 18), 95% CI -0.67 to +0.19. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.30 (p 0.221, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.32 (p 0.198, n 18). could be the mix.
skeptic: leave-one-out range -0.40 to -0.21, sign flips 0; without severely affected donors -0.30 (p 0.221, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NFASC in dopamine neurons.

case closed: nothing better to follow up.

receipt 9640: NFASC in oligodendrocytes, braak

power: full sample -0.56 (p 0.016, n 18), 95% CI -0.81 to -0.12. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.56 (p 0.016, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.56 (p 0.016, n 18). not the mix.
skeptic: leave-one-out range -0.69 to -0.50, sign flips 0; without severely affected donors -0.56 (p 0.016, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NFASC in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts